MAM
Publicis launches global employee-first programme – ‘Work Your World’
Mumbai: Publicis Group has announced ‘Work Your World,’ a global employee-first programme that will allow every employee of the company to work from any accessible country where the group is present, for up to six weeks a year, starting from January 2022.
“We have been working hard on how to turn the hybrid world into new opportunities for everyone at Publicis, and make the future of work more creative and more daring,” said Publicis Groupe global chairman and CEO Arthur Sadoun, adding, “We know the pandemic isn’t over, and we know that the world could close again at any time. But that’s not a reason to close our horizons and perspectives. We will continue to move forward, because one day this crisis will come to an end and because we owe it to our people to make their professional and personal experience at Publicis truly unique.”
Through this initiative that draws on the group’s heritage and values like ‘Viva La Difference,’ every employee will have the chance to access the program and experience other offices, cultures and lifestyles, via its collaborative community, said the company. It will be sharing more details on ‘Work Your World’ at the group’s second Viva La Différence seminar on its AI platform in December, it further said.
“Our people have been incredibly resourceful despite the limitations of the pandemic. They deserve to work for a company as resourceful as they are. Work Your World can help every Publicis employee ‘work their world’ in a bigger, better and brighter way thanks to our scale, diversity and Marcel,” said Publicis Groupe global CSO Carla Serrano.
Through the landing page on Marcel- its custom-made AI platform, employees will be able to: Browse local and global destinations, in over 100 countries where Publicis has offices and see dynamic updates on accessible countries and locations, with information on local health and business regulations, to take the necessary measures and precautions before travel.
In a future-facing initiative, the employees would also be able to find accommodation through a feature open to the Publicis community called Home Swap Home that enables them to share and swap accommodation with colleagues.
Additionally, they can connect with other employees in different countries, via Marcel’s profile intelligence, to discover what it’s like to live and work in a given location, and access a dedicated 24-hour contact center, to receive real-time support from experts for questions related to travel, health regulations, visas, and work permits.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
